Mortality in men with locally advanced prostate cancer was reduced by half when they were treated with a combination of radiation treatment and hormone therapy, compared with hormone therapy alone, according to a study published online ahead of print January 5 in the Journal of Clinical Oncology. 


Justin E. Bekelman, MD, and colleagues followed 31,541 men with prostate cancer aged 65 to 85 years. They found a reduction in mortality of 57% among men aged 65 to 75 years and 49% among men aged 76 to 85 years who received radiation and hormone therapy, compared with hormone therapy alone. The combination of radiation and hormone therapy was also associated with approximately one-third fewer deaths from any cause.


“Older men with locally advanced or screen-detected high-risk prostate cancer who receive androgen-deprivation therapy alone risk decrements in cause-specific and overall survival,” stated Dr. Bekelman.